ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage biotechnology company headquartered at the Biopôle in Lausanne, Switzerland, with US operations in New Jersey, that discovers and develops antibody drug conjugates (ADCs) for hematologic malignancies and solid tumors. Its approved product ZYNLONTA (loncastuximab tesirine-lpyl) is a CD19-directed ADC for relapsed or refractory diffuse large B-cell lymphoma, and the company is expanding it into earlier lines through the LOTIS-5 Phase 3 and LOTIS-7 Phase 1b trials alongside a preclinical and clinical ADC pipeline. It is a therapeutics developer, not a software vendor: a 2026-09-07 probe of every host it operates found no developer portal, no public API, no SDK and no machine-readable contract.
ADC Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Life Sciences.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: adc-therapeutics
name: ADC Therapeutics
description: 'ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage biotechnology company headquartered at the Biopôle in
Lausanne, Switzerland, with US operations in New Jersey, that discovers and develops antibody drug conjugates (ADCs) for
hematologic malignancies and solid tumors. Its approved product ZYNLONTA (loncastuximab tesirine-lpyl) is a CD19-directed
ADC for relapsed or refractory diffuse large B-cell lymphoma, and the company is expanding it into earlier lines through
the LOTIS-5 Phase 3 and LOTIS-7 Phase 1b trials alongside a preclinical and clinical ADC pipeline. It is a therapeutics
developer, not a software vendor: a 2026-09-07 probe of every host it operates found no developer portal, no public API,
no SDK and no machine-readable contract.'
image: https://www.adctherapeutics.com/wp-content/uploads/2026/03/adc-logo.png
url: https://raw.githubusercontent.com/api-evangelist/adc-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-07'
modified: '2026-09-07'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Life Sciences
- Healthcare
- Clinical Trials
- Antibody Drug Conjugates
x-enrichment:
date: '2026-09-07'
status: minimal
artifacts_added: 3
pass: local-v3
x-coverage:
state: none
reason: not-a-software-company
detail: 'ADC Therapeutics is an oncology drug developer whose product is ZYNLONTA, not software: its WordPress corporate
site serves no /developers, /api or /llms.txt path, its Q4-hosted investor site answers every unknown path with a 200
HTML soft-404, no npm/PyPI package carries its name, and no /.well-known/ discovery document exists on any of its five
hosts.'
evidence:
- url: https://www.adctherapeutics.com/developers
status: 404
- url: https://www.adctherapeutics.com/openapi.json
status: 404
- url: https://www.adctherapeutics.com/llms.txt
status: 404
- url: https://www.adctherapeutics.com/.well-known/agent-card.json
status: 404
- url: https://api.github.com/orgs/adctherapeutics
status: 404
checked: '2026-09-07'
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/adc-therapeutics-domain-security.yml
- type: Website
url: https://www.adctherapeutics.com/
- type: PrivacyPolicy
url: https://www.adctherapeutics.com/privacy-policy/
- type: TermsOfService
url: https://www.adctherapeutics.com/legal-notice/
- type: Contact
url: https://www.adctherapeutics.com/about-adc-therapeutics/contact/
- type: InvestorRelations
url: https://ir.adctherapeutics.com/overview
- type: Careers
url: https://www.adctherapeutics.com/culture-careers/culture/
- type: About
url: https://www.adctherapeutics.com/about-adc-therapeutics/leadership/
- type: LLMsTxt
url: llms/adc-therapeutics-llms.txt
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →